Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Research Determines Why Different Cancers Display Similar Profiles

By LabMedica International staff writers
Posted on 17 Oct 2018
A team of cancer researchers has identified a molecular mechanism that may explain why gene expression profiles are similar in late stage cancers from different organs.

The use of modern chemotherapeutic techniques to treat epithelial cancers leads to the development of multiple resistance mechanisms, including the generation of highly aggressive, small cell neuroendocrine carcinoma (SCNC). More...
SCNC patients have a poor prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. In particular, whether distinct cancer types accomplish this “reprogramming” through the same mechanism has been unclear.

Investigators at the University of California, Los Angeles (USA) reported in the October 5, 2018, issue of the journal Science that while healthy prostate and lung cells have very different patterns of gene expression, they display almost identical patterns when they transform into small cell cancers.

The investigators found that a common set of defined oncogenic drivers reproducibly reprogrammed normal human prostate and lung epithelial cells and transformed them into small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. They identified shared active transcription factor binding regions in the reprogrammed prostate and lung SCNCs by integrative analyses of epigenetic and transcriptional landscapes.

"Small cell cancers of the lung, prostate, bladder, and other tissues were long thought to be similar in name alone - and they were treated by oncologists as different entities," said senior author Dr. Owen Witte, professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. "Over the past few years, though, researchers have increasingly begun to realize that there are similarities in the cancers, and that's what our work confirms. Our study revealed shared "master gene regulators" - the key proteins that control expression of multiple genes in small cell cancer cells. Studying the network of the master gene regulators could lead to a new way of combating deadly cancers."

Overall, the results presented in this study suggest that neuroendocrine cancers arising from distinct epithelial tissues may share common vulnerabilities that could be exploited for the development of new drugs to treat SCNCs.

Related Links:
University of California, Los Angeles


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies (Photo courtesy of Salgia NJ et al., Cancer Cell, 2025)

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers

Sarcomatoid renal cell carcinoma (sRCC) is a rare, aggressive form of kidney cancer comprising about 5% of cases and is typically diagnosed at late stages. Resistant to most therapies, it has shown unusually... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.